18522-95-7

Basic information

• Product Name: Ethyl 2-(Methylamino)-2-Oxoacetate
• Synonyms: Ethyl 2-(Methylamino)-2-Oxoacetate;Ethyl (methylcarbamoyl)formate
• CAS NO: 18522-95-7
• Molecular Formula: C₅H₉NO₃
• Molecular Weight: 131.13
• Mol File: 18522-95-7.mol
• Article Data: 8

Chemical Properties

• Melting Point: 24 °C
• Appearance: /
• Density: 1.088±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform; Dichloromethane; Ethyl Acetate; Methanol; DMF
• PKA: 12.77±0.46(Predicted)
• CAS DataBase Reference: Ethyl 2-(Methylamino)-2-Oxoacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(Methylamino)-2-Oxoacetate(18522-95-7)
• EPA Substance Registry System: Ethyl 2-(Methylamino)-2-Oxoacetate(18522-95-7)

Safety Data

• Hazardous Substances Data: 18522-95-7(Hazardous Substances Data)

Upstream product

• 96-31-1 N,N'-Dimethylurea 
• 95-92-1 oxalic acid diethyl ester 
• 4755-77-5 Ethyl oxalyl chloride 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 22509-04-2 N-Methyl-oxamid 
• 23206-49-7 N-Methyl-2-(3-nitro-benzenesulfonylamino)-2-oxo-acetamide 
• 208771-95-3 4-methyl-2-(N-methylcarbamoyl)-1 H-benzimidazole 
• 73185-68-9 benzoylhydrazono-methylamino-acetic acid ethyl ester 
• 73185-71-4 methylamino-(2-oxo-2-phenyl-ethylimino)-acetic acid ethyl ester 
• 71243-30-6 benzimidazole-2-carboxylic acid N-methylamide 
• 6170-89-4 N-Methyl-N'-p-toluolsulfonyl-oxalsaeure-diamid 
• 73188-60-0 Chloro(methylimino)acetic acid ethyl ester 
• 615-35-0 N,N'-dimethyloxamide 
• 10605-18-2 N-Methyl-N-phenyl oxamide 

Relevant articles and documents

GRK2 INHIBITORS AND USES THEREOF

The present disclosure features useful methods to treat cancer, e.g., in a subject in need thereof. The methods described herein are useful in the treatment of disorders associated with GRK2 expression, e.g., cancer or cardiovascular disease. The present disclosure also features compounds (e.g., GRK2 inhibitors), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof.

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION

The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) for use in treating or reducing the risk of deve